Uniswap V4 Launch: Revolutionizing DeFi Worldby John Darbie 16.02.2024The Uniswap Foundation announces the launch of 'Uniswap v4' following Ethereum's Dencun upgrade. Uniswap's native token, UNI, shows a bullish ...
Arbitrum (ARB) Price Dips Amid Volatile Week Surgeby John Darbie 16.02.2024Arbitrum (ARB) has seen a 6.16% price decrease in the last 24 hours, contradicting its positive performance over the past ...
Lido DAO’s Rollercoaster Week: Price and Growth Analysisby John Darbie 16.02.2024Lido DAO's price has dropped by 3.29% in the past 24 hours, contrasting its recent upward trend. Despite this decrease, ...
Solana Emerges as Crypto Powerhouse: 380% Surge!by John Darbie 16.02.2024Solana has become the fifth-largest crypto with a 380% growth in 12 months, driven by developments and high returns. Their ...
Navigating the Crypto Boom: Expert Paths to Richesby John Darbie 16.02.2024The promise and volatility of the crypto stocks market require insight and caution. Investing in crypto stocks provides diversification and ...
Solana Surpasses Binance Coin, Ethereum Eyes $3k, DeeStream Growthby John Darbie 16.02.2024Solana (SOL) surpasses Binance Coin, Ethereum eyes $3,000, and DeeStream attracts ETH and SOL holders to its presale. Positive growth ...
Iridium Adjusts Amid Starlink Rivalry: Hold or Buy?by Mark Eisenberg 16.02.2024Iridium Communications' rating has shifted from Buy to Hold, due to accounting changes and increased competition. Potential value through inventory ...
Cellebrite Stock Upgraded by BofA: Buy Now!by Mark Eisenberg 16.02.2024Bank of America Securities upgrades Cellebrite stock to Buy, increasing price target to $12. Improved business momentum and strong market ...
Ethereum Price Surge: Will BTC Halving Drive Growth?by John Darbie 16.02.2024Ethereum's price outlook after the Bitcoin halving suggests potential fluctuations. Historical trends predict a range of $8,000 to $12,000, with ...
Biohaven Pharmaceutical: RBC’s $62 Target and Growthby Mark Eisenberg 16.02.2024RBC Capital Markets initiates coverage on Biohaven Pharmaceutical, assigning an outperform rating with a $62 price target. The firm praises ...